AUPH
Aurinia Pharmaceuticals Inc. (NASDAQ)
Healthcare — Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
None
7 analysts
$16.97
+$-1.17 (+1.07%)
Target:
$17.00
(0.2%)
Sign in to add AUPH to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $2.18B |
| P/E Ratio (TTM) | 7.86 |
| Forward P/E | 15.18 |
| EPS (TTM) | $2.16 |
| Dividend Yield | - |
| Profit Margin | 99.97% |
| Revenue Growth | 24.40% |
| ROE | 64.98% |
| Debt/Equity | 12.09 |
| Recommendation | None |
| Analyst Target | $17.00 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 61.2 |
| Beta | 1.43 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $19.25 |
| 52-Week Low | $7.29 |
| 50-Day Avg | $15.98 |
| 200-Day Avg | $14.74 |
| Avg Volume | $1.39M |
| Volume | $2.03M |
Performance Analysis
BULLISHAUPH shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 81% of its 52-week range.
+
RSI at 61.2 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
P/E of 7.9 suggests the stock may be undervalued.
+
Strong revenue growth of 24.4% year-over-year.
+
Healthy profit margin of 100.0%.
~
Wall Street consensus is "none" from 7 analysts.
+
Average analyst target of $17.00 implies 0.2% upside.
Recent News
Loading news...
Last updated: Jun 30, 2026 21:08 UTC
Back to Screener Export Report